Eli Lilly and Company announce results of Alzheimer’s drug trial
New England Council member, Eli Lilly and Company, presented the results of its phase 3 trial for donanemab at the Alzheimer’s Association International Conference.
The drug has seen remarkable success in its trials, substantially slowing cognitive decline in amyloid-positive Alzheimer’s patients. Its greatest effects were on those in the earliest stages of the disease development, delaying the decline of patients’ cognitive ability by 60% relative to the placebo. Additionally, the effectiveness of donanemab continued to grow throughout the length of the trial, with the greatest differences compared to placebo evident at the end of the 18-month trial period. Eli Lilly expects a regulatory decision from the FDA on donanemab by the end of the year.
“If approved, we believe donanemab can provide clinically meaningful benefits for people with this disease and the possibility of completing their course of treatment as early as 6 months,” said Anne White, Vice President of Eli Lilly.
The New England Council would like to commend Eli Lilly and Company for its commitment to treating people with Alzheimer’s disease.
Read more from Eli Lilly and Company.